Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Average Recommendation of “Buy” from Brokerages

Structure Therapeutics Inc. (NASDAQ:GPCR) has been assigned an average rating of “Buy” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $81.29.

Several research firms have commented on GPCR. JMP Securities restated a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a research report on Thursday, December 19th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after acquiring an additional 1,122 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in shares of Structure Therapeutics in the 4th quarter worth approximately $40,000. Assetmark Inc. lifted its stake in Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after purchasing an additional 719 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after buying an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC acquired a new position in Structure Therapeutics in the third quarter worth approximately $202,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

Structure Therapeutics stock opened at $29.97 on Monday. Structure Therapeutics has a one year low of $23.50 and a one year high of $62.74. The company has a 50-day simple moving average of $29.65 and a 200-day simple moving average of $35.20.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.